MO Money Moves On to Infinity Pharmaceuticals (INFI $41.10)Up 16%

The BIG money in biotech has moved on to new names like Infinity (INFI) up 15 points since December. In the meantime they are moving out of the big winners from 2012 like Alexion (ALXN  $83.4) down 3% and Regeneron (REGN $160) down 2.7% . See previous postings.

The tremendous liquidity in this market can take biotech favs anywhere because valuation metrics do not matter. All that matters is good science, good news and sponsorship from BIG money. And apparently Infinity (INFI) qualifies as an undiscovered stock because excellent Phase 2 clinical data is expected.

More later this week.

No comments yet.

Leave a Reply